| Business Summary | | Immunogen,
Inc.
develops
pharmaceuticals,
primarily
for
the
treatment
of
cancer.
The
Company's
product
candidates
are
tumor-activated
prodrugs
(TAPs).
They
are
based
on
the
Company's
proprietary
technology
platform,
which
combines
monoclonal
antibodies
that
target
tumor
cells,
and
potent
drugs.
Together
with
partners,
the
Company
is
currently
developing
two
TAP
product
candidates.
The
Company
has
also
initiated
a
licensing
program
that
allows
it
to
generate
cash
flow
through
granting
rights
to
other
companies
to
use
portions
of
its
TAP
technology
in
their
product
development
programs.
The
Company
can
use
this
revenue
from
technology
licenses
to
support
research
to
identify
new
targets
for
TAPs
and
fund
research
and
development
of
internal
TAP
products,
which
the
Company
may
commercialize
on
its
own
or
with
partners. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Immunogen
develops,
produces,
and
markets
commercial
anti-cancer
and
other
biopharmaceutical
products
based
on
molecular
immunology.
For
the
fiscal
year
ended
6/01,
revenues
fell
60%
to
$4.5
million.
Net
loss
before
accounting
change
rose
from
$237
thousand
to
$9.6
million.
Revenues
reflect
lower
collaboration
payments
received
under
the
SmithKline
Beecham
agreement.
Net
loss
also
reflects
higher
research
and
development
costs
related
to
Phase
I
cancer
product
huC242-DM1/SB-408075. Recent
Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
525;
after
tax
earnings
were
-3,277. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Mitchel Sayare, Ph.D., 52 Chairman,
Pres, CEO | $333K | Gregg Beloff CFO, VP | -- | Walter Blattler, Ph.D., 51 Exec.
VP - Science and Technology, Treasurer, Director | 265K | John Lambert, Ph.D., 49 Sr.
VP, Pharmaceutical Devel. | 184K | Pauline Ryan, 33 VP-Bus.
Devel. | 142K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|